Related Experiment Video
Updated: Feb 9, 2026
09:22
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
12.6K
Chronic Thromboembolic Pulmonary Hypertension.
Stuart Jamieson1, G Victor Pretorius1
1Division of Cardiovascular and Thoracic Surgery, University of California, San Diego, California.
Seminars in Interventional Radiology
|June 7, 2018
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) results from unresolved blood clots causing lung artery obstruction and right heart failure. Pulmonary artery endarterectomy surgery offers a curative treatment option with low mortality at specialized centers.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Surgery
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) arises from incompletely resolved acute pulmonary emboli.
- Fibrotic scar tissue obstructs pulmonary arteries, leading to progressive right heart failure.
- Current medical therapies for CTEPH are primarily supportive.
Purpose of the Study:
- To highlight the pathophysiology of CTEPH.
- To emphasize the curative potential of pulmonary artery endarterectomy.
- To underscore the importance of experienced surgical centers for managing CTEPH.
Main Methods:
- Review of the pathophysiology of chronic thromboembolic pulmonary hypertension.
- Analysis of treatment outcomes for pulmonary artery endarterectomy.
- Evaluation of mortality rates in experienced surgical centers.
Main Results:
- Pulmonary artery endarterectomy is a curative surgical intervention for CTEPH.
- Surgical treatment is associated with low mortality rates when performed at experienced centers.
- Medical management provides supportive care but does not resolve the underlying obstruction.
Conclusions:
- Pulmonary artery endarterectomy is the definitive treatment for chronic thromboembolic pulmonary hypertension.
- Successful surgical outcomes for CTEPH are dependent on surgical expertise and center volume.
- Prompt surgical intervention can prevent irreversible right heart failure in CTEPH patients.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
664
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
664
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
618
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
618
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.2K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.2K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.7K